Genentech, a subsidiary of Roche Holding AG (RHHBY), Friday announced a new 5-year data confirming benefit of Evrysdi for the children with Type 1 spinal muscular atrophy or SMA as they were able to sit, stand and walk.
SMA is a progressive neuromuscular disease that affects the functioning of nerve cells, affecting the patient's ability to walk, eat or breathe.
By the end of the Firefish study, 91 percent of children treated with Evrysdi were alive, 81 percent were alive without permanent ventilation and the majority were able to sit without support for at least 30 seconds, the company stated.
Also, 96 percent of patients were able to swallow, and 80 percent were able to feed without the help of a feeding tube by the end of 5 years.
Currently, Genentech's stock is trading at $33.92, up 1.31 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.